(4R)-4-ethyl-1,3-oxazolidin-2-one → (R)-3-{4-[4-(3,5-dicyclopropylpyridin-2-yl)piperazine-1-carbonyl]-3-methanesulfonylphenyl}-4-ethyloxazolidin-2-one
반응식
Br[C:2]1[CH:7]=[CH:6][C:5]([C:8]([N:10]2[CH2:15][CH2:14][N:13]([C:16]3[C:21]([CH:22]4[CH2:24][CH2:23]4)=[CH:20][C:19]([CH:25]4[CH2:27][CH2:26]4)=[CH:18][N:17]=3)[CH2:12][CH2:11]2)=[O:9])=[C:4]([S:28]([CH3:31])(=[O:30])=[O:29])[CH:3]=1.[CH2:32]([C@@H:34]1[CH2:38][O:37][C:36](=[O:39])[NH:35]1)[CH3:33]>>[CH:22]1([C:21]2[C:16]([N:13]3[CH2:14][CH2:15][N:10]([C:8]([C:5]4[CH:6]=[CH:7][C:2]([N:35]5[C@H:34]([CH2:32][CH3:33])[CH2:38][O:37][C:36]5=[O:39])=[CH:3][C:4]=4[S:28]([CH3:31])(=[O:30])=[O:29])=[O:9])[CH2:11][CH2:12]3)=[N:17][CH:18]=[C:19]([CH:25]3[CH2:27][CH2:26]3)[CH:20]=2)[CH2:24][CH2:23]1참가 물질
3
실험 절차
By reaction and treatment in the same manner as in Example 111 and using (4-bromo-2-methanesulfonylphenyl)[4-(3,5-dicyclopropylpyridin-2-yl)piperazin-1-yl]methanone (400 mg) described in Preparation Example 89 and (R)-4-ethyloxazolidin-2-one (91.3 mg) described in Preparation Example 26, the title compound (109.5 mg) was obtained.
후처리
- customBy reaction and treatment in the same manner as in Example 111
- customdescribed in Preparation Example 26
출처 및 근거
- ORD 기록
- ord-3c6cb6391ab0440eb8db0e52161ecdb9
- 출처 데이터셋
- uspto-grants-2013_01
- 특허 번호
- US08354401B2
반응 노트
불러오는 중…